Last 12 months
Inside the activity.
5 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 5 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 4 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2020 Filed Jun 25, 2020 20:01 UTC |
Fletcher Aaron G.L.Director
|
PurchaseCommon Stock | 2,953 | $25.24 | $74,533.72 |
DisclosureSEC source: 0001209191-20-038885 · doc4.xml · nonDerivative · entry 2 Fletcher Aaron G.L. · CIK 0001789490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,452 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.91 to $25.74, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:01 UTC |
Fletcher Aaron G.L.Director
|
PurchaseCommon Stock | 4,547 | $24.64 | $112,038.08 |
DisclosureSEC source: 0001209191-20-038885 · doc4.xml · nonDerivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,499 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.92 to $24.90, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:18 UTC |
Morich FrankDirector
|
GrantStock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $27.56 | $0.00 |
DisclosureSEC source: 0001209191-20-028490 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2030-05-11 F1 · shares: Represents a stock option award granted on May 11, 2020 pursuant to the Issuer's 2016 Omnibus Incentive Plan. Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · derivative · entry 4 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,001 Underlying: Common Stock · 16,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. F2 · derivative.expiration_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC |
Suri AnishPresident and CSO
|
GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,667 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. F2 · derivative.expiration_date: Represents an award of restricted stock units granted on March 31, 2020 pursuant to the reporting person's employment agreement. The restricted stock units vest in three equal annual installments beginning on March 31, 2020. Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC |
Suri AnishPresident and CSO
|
Tax withholdingCommon Stock | 5,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,558 Read SEC document |
| March 31, 2020 Filed Apr 10, 2020 22:25 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024164 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 16:11 UTC |
Pienta KennethChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021239 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 24, 2020. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 21:53 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008815 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 16:49 UTC |
PASSERI DANIEL RDirector · CEO
|
GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008793 · doc4.xml · derivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: One-half of the restricted stock units vest on September 30, 2021 and the balance vest on March 31, 2022. F3 · derivative.expiration_date: One-half of the restricted stock units vest on September 30, 2021 and the balance vest on March 31, 2022. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 16:49 UTC |
PASSERI DANIEL RDirector · CEO
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008793 · doc4.xml · derivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 21:52 UTC |
Millar Kerri-AnnVP-Finance
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008809 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 21:51 UTC |
Suri AnishPresident and CSO
|
GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008800 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:57 UTC |
MARLETT CHRISTOPHER ADirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002061 · doc4.xml · derivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:52 UTC |
DRISCOLL FREDERICK WDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002057 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:02 UTC |
Simon Barry J.Director
|
GrantStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002066 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:58 UTC |
MCKNIGHT STEVEN LDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002063 · doc4.xml · derivative · entry 1 MCKNIGHT STEVEN L · CIK 0001182470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:55 UTC |
Kiener Peter ADirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002060 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:54 UTC |
Gray CameronDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002058 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:01 UTC |
Morich FrankDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002064 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:49 UTC |
Fletcher Aaron G.L.Director
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002054 · doc4.xml · derivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Director Compensation Policy. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 23:26 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 9,000 | $15.71 | $141,390.00 |
DisclosureSEC source: 0001209191-19-062325 · doc4.xml · nonDerivative · entry 3 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $15.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 31, 2019 Filed Dec 31, 2019 23:26 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 6,700 | $15.77 | $105,659.00 |
DisclosureSEC source: 0001209191-19-062325 · doc4.xml · nonDerivative · entry 2 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 768,503 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 23:26 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 9,000 | $17.24 | $155,160.00 |
DisclosureSEC source: 0001209191-19-062325 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 775,203 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.56, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 26, 2019 Filed Dec 27, 2019 21:39 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 19,647 | $17.53 | $344,411.91 |
DisclosureSEC source: 0001209191-19-062031 · doc4.xml · nonDerivative · entry 2 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 784,203 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.35 to $17.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 23, 2019 Filed Dec 27, 2019 21:39 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 17,000 | $16.82 | $285,940.00 |
DisclosureSEC source: 0001209191-19-062031 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 803,850 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.44 to $17.00, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 19, 2019 Filed Dec 19, 2019 22:35 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 4,000 | $17.00 | $68,000.00 |
DisclosureSEC source: 0001209191-19-061377 · doc4.xml · nonDerivative · entry 4 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 820,850 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:35 UTC |
MARLETT CHRISTOPHER ADirector
|
SaleCommon Stock | 20,732 | $15.73 | $326,114.36 |
DisclosureSEC source: 0001209191-19-061377 · doc4.xml · nonDerivative · entry 3 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 824,850 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $16.38, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 12, 2019 Filed Dec 19, 2019 22:35 UTC |
MARLETT CHRISTOPHER ADirector
|
OtherCommon Stock | 755,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061377 · doc4.xml · nonDerivative · entry 2 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 845,582 F1 · kind: Pro rata distribution from MDB Capital Group, LLC ("MDB"). F3 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 12, 2019 Filed Dec 19, 2019 22:35 UTC |
MARLETT CHRISTOPHER ADirector
|
OtherCommon Stock | 1,007,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061377 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Pro rata distribution from MDB Capital Group, LLC ("MDB"). F2 · ownership.nature: The record owner of these securities is MDB. The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:34 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionRestricted Stock Units · Derivative | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054991 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. F2 · derivative.expiration_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. F2 · derivative.underlying: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:34 UTC |
Suri AnishPresident and CSO
|
Tax withholdingCommon Stock | 12,087 | $8.63 | $104,310.81 |
DisclosureSEC source: 0001209191-19-054991 · doc4.xml · nonDerivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,246 Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 22:34 UTC |
Suri AnishPresident and CSO
|
Exercise / conversionCommon Stock | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-054991 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:15 UTC |
Fletcher Aaron G.L.Director
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001209191-19-052715 · doc4.xml · derivative · entry 3 Fletcher Aaron G.L. · CIK 0001789490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-10-03 F2 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning April 3, 2020. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:12 UTC |
Suri AnishPresident and CSO
|
GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-052713 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. F3 · derivative.expiration_date: Represents a restricted stock unit award granted on October 3, 2019. The restricted stock units vest in three equal annual installments beginning on October 3, 2019. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:12 UTC |
Suri AnishPresident and CSO
|
GrantStock Option (right to buy) · Derivative | 400,000 | $7.53 Strike: $7.53 | $3,012,000.00 |
DisclosureSEC source: 0001209191-19-052713 · doc4.xml · derivative · entry 2 Suri Anish · CIK 0001739130 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning April 3, 2020. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 16:09 UTC |
PASSERI DANIEL RDirector · CEO and President
|
PurchaseCommon Stock | 1,377 | $7.26 | $9,997.02 |
DisclosureSEC source: 0001209191-19-038900 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,977 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.25 to $7.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 10, 2019 Filed Jun 10, 2019 22:16 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
PurchaseCommon Stock | 14,938 | $7.93 | $118,458.34 |
DisclosureSEC source: 0001209191-19-035958 · doc4.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 10, 2019 Filed Feb 24, 2020 21:56 UTC Amendment |
Sandercock ColinSVP, General Counsel and Sec
|
PurchaseCommon Stock | 15,025 | $7.90 | $118,697.50 |
DisclosureSEC source: 0001209191-20-012027 · doc4a.xml · nonDerivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,125 F2 · shares: 87 of these shares were inadvertantly omitted from the Original Form 4, which reported a purchase of 14,938 shares of common stock on June 10, 2019 at a weighted average price of $7.93. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.85 to $7.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 07, 2019 Filed Feb 24, 2020 21:56 UTC Amendment |
Sandercock ColinSVP, General Counsel and Sec
|
PurchaseCommon Stock | 100 | $7.35 | $735.00 |
DisclosureSEC source: 0001209191-20-012027 · doc4a.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 F1 · shares: This transaction was inadvertantly omitted from the reporting person's original Form 4 filed on June 10, 2019 (the "Original Form 4"). Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:12 UTC |
PASSERI DANIEL RDirector · CEO and President
|
PurchaseCommon Stock | 3,000 | $6.90 | $20,700.00 |
DisclosureSEC source: 0001209191-19-035525 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.88 to $6.92, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 22:16 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
PurchaseCommon Stock | 2,000 | $7.10 | $14,200.00 |
DisclosureSEC source: 0001209191-19-035958 · doc4.xml · nonDerivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.04 to $7.16, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:13 UTC |
Mancilla BethanySVP and Chief Business Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001209191-19-018088 · doc4.xml · derivative · entry 2 Mancilla Bethany · CIK 0001748840 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-08-01 F2 · derivative.exercise_date: Represents a stock option award granted on August 1, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:13 UTC |
Mancilla BethanySVP and Chief Business Officer
|
GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018088 · doc4.xml · derivative · entry 1 Mancilla Bethany · CIK 0001748840 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:10 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-19-018084 · doc4.xml · derivative · entry 2 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-12-27 F2 · derivative.exercise_date: Represents a stock option award granted on December 27, 2017 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 65,000 of these options were vested and exercisable. The remaining 35,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:10 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018084 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:17 UTC |
PASSERI DANIEL RDirector · CEO and President
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-19-018091 · doc4.xml · derivative · entry 3 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-07-23 F2 · derivative.exercise_date: Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:17 UTC |
PASSERI DANIEL RDirector · CEO and President
|
GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018091 · doc4.xml · derivative · entry 2 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:16 UTC |
Suri AnishChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-19-018090 · doc4.xml · derivative · entry 3 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-07-23 F2 · derivative.exercise_date: Represents a stock option award granted on July 23, 2018 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 50,000 of these options were vested and exercisable. The remaining 50,000 will become vested and exercisable only upon the achievement of certain performance based conditions. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:16 UTC |
Suri AnishChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018090 · doc4.xml · derivative · entry 2 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.